Single-center, randomized, double-blind, double-dummy, active and placebo-controlled, five-period crossover trial of intranasal morphine [Egalet-001] versus MS Contin for the treatment of pain in non-dependent, recreational opioid users [Category 3 abuse-deterrent intranasal HAL study]
Phase of Trial: Phase II
Latest Information Update: 20 May 2017
At a glance
- Drugs Morphine (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Egalet
- 20 May 2017 Results of this and another phase I study presented at the 36th Annual Scientific Meeting of the American Pain Society.
- 22 Sep 2016 Results published in an Egalet media release.
- 22 Sep 2016 Results from this and intranasal abuse potential trial (see CTP 700252740) published in Pain Medicine, according to an Egalet Corporation media release.